Gedyt /ID# 258984

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D. 1115

0 studies enrolling now · 1 studies all time

What they study most

Crohn's Disease

Studies at this site

• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Running, not enrolling